A novel method to assess platelet inhibition by eptifibatide with thrombelastograph®

Nobuyuki Katori, Fania Szlam, Jerrold H. Levy, Kenichi A. Tanaka

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We examined a novel method to detect platelet inhibition with thrombelastography (TEG®). We hypothesized that this method would be suitable for monitoring the antiplatelet effects of eptifibatide (Integrilin®). Whole blood from healthy volunteers was anticoagulated with 3.2% citrate or unfractionated heparin (7 IU/ mL). For the platelet aggregation test, both citrate and heparinized samples were spiked with increasing concentrations of eptifibatide (0, 0.2, 0.4, 0.8, 1.6, and 4 μg/mL). Conventional kaolin TEG® was performed with citrated samples, and batroxobin-modified TEG® was performed with heparinized samples, which were spiked with eptifibatide at concentrations of 0, 0.4, 0.8, 1.6, 4, 8, and 24 μg/mL. Adenosine 5′-diphosphate-induced platelet aggregation was reduced to 6.4% ± 2.9% (citrate) and 10.3% ± 4.8% (heparin) with eptifibatide at the concentration of 4 μg/mL. The kaolin TEG® showed a decrease in maximum amplitude (MA) only at the eptifibatide concentration of 24 μg/mL and no change in a angle, whereas with the batroxobin-based TEG®, the difference in MA and α angle was observed at concentrations ≥0.8 μg/mL. Additionally, the time to achieve maximum MA was much shorter for batroxobin TEG® than for kaolin TEG®. We conclude that the batroxobin-modified TEG® is a sensitive method that detects platelet inhibition induced by eptifibatide.

Original languageEnglish
Pages (from-to)1794-1799
Number of pages6
JournalAnesthesia and Analgesia
Volume99
Issue number6
DOIs
Publication statusPublished - 2004 Dec
Externally publishedYes

Fingerprint

Thrombelastography
Blood Platelets
Batroxobin
Kaolin
Citric Acid
Platelet Aggregation
Heparin
eptifibatide
Adenosine Diphosphate
Healthy Volunteers

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

A novel method to assess platelet inhibition by eptifibatide with thrombelastograph®. / Katori, Nobuyuki; Szlam, Fania; Levy, Jerrold H.; Tanaka, Kenichi A.

In: Anesthesia and Analgesia, Vol. 99, No. 6, 12.2004, p. 1794-1799.

Research output: Contribution to journalArticle

Katori, Nobuyuki ; Szlam, Fania ; Levy, Jerrold H. ; Tanaka, Kenichi A. / A novel method to assess platelet inhibition by eptifibatide with thrombelastograph®. In: Anesthesia and Analgesia. 2004 ; Vol. 99, No. 6. pp. 1794-1799.
@article{a1155d158bcb4779b2191efbc9279368,
title = "A novel method to assess platelet inhibition by eptifibatide with thrombelastograph{\circledR}",
abstract = "We examined a novel method to detect platelet inhibition with thrombelastography (TEG{\circledR}). We hypothesized that this method would be suitable for monitoring the antiplatelet effects of eptifibatide (Integrilin{\circledR}). Whole blood from healthy volunteers was anticoagulated with 3.2{\%} citrate or unfractionated heparin (7 IU/ mL). For the platelet aggregation test, both citrate and heparinized samples were spiked with increasing concentrations of eptifibatide (0, 0.2, 0.4, 0.8, 1.6, and 4 μg/mL). Conventional kaolin TEG{\circledR} was performed with citrated samples, and batroxobin-modified TEG{\circledR} was performed with heparinized samples, which were spiked with eptifibatide at concentrations of 0, 0.4, 0.8, 1.6, 4, 8, and 24 μg/mL. Adenosine 5′-diphosphate-induced platelet aggregation was reduced to 6.4{\%} ± 2.9{\%} (citrate) and 10.3{\%} ± 4.8{\%} (heparin) with eptifibatide at the concentration of 4 μg/mL. The kaolin TEG{\circledR} showed a decrease in maximum amplitude (MA) only at the eptifibatide concentration of 24 μg/mL and no change in a angle, whereas with the batroxobin-based TEG{\circledR}, the difference in MA and α angle was observed at concentrations ≥0.8 μg/mL. Additionally, the time to achieve maximum MA was much shorter for batroxobin TEG{\circledR} than for kaolin TEG{\circledR}. We conclude that the batroxobin-modified TEG{\circledR} is a sensitive method that detects platelet inhibition induced by eptifibatide.",
author = "Nobuyuki Katori and Fania Szlam and Levy, {Jerrold H.} and Tanaka, {Kenichi A.}",
year = "2004",
month = "12",
doi = "10.1213/01.ANE.0000136476.82598.88",
language = "English",
volume = "99",
pages = "1794--1799",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A novel method to assess platelet inhibition by eptifibatide with thrombelastograph®

AU - Katori, Nobuyuki

AU - Szlam, Fania

AU - Levy, Jerrold H.

AU - Tanaka, Kenichi A.

PY - 2004/12

Y1 - 2004/12

N2 - We examined a novel method to detect platelet inhibition with thrombelastography (TEG®). We hypothesized that this method would be suitable for monitoring the antiplatelet effects of eptifibatide (Integrilin®). Whole blood from healthy volunteers was anticoagulated with 3.2% citrate or unfractionated heparin (7 IU/ mL). For the platelet aggregation test, both citrate and heparinized samples were spiked with increasing concentrations of eptifibatide (0, 0.2, 0.4, 0.8, 1.6, and 4 μg/mL). Conventional kaolin TEG® was performed with citrated samples, and batroxobin-modified TEG® was performed with heparinized samples, which were spiked with eptifibatide at concentrations of 0, 0.4, 0.8, 1.6, 4, 8, and 24 μg/mL. Adenosine 5′-diphosphate-induced platelet aggregation was reduced to 6.4% ± 2.9% (citrate) and 10.3% ± 4.8% (heparin) with eptifibatide at the concentration of 4 μg/mL. The kaolin TEG® showed a decrease in maximum amplitude (MA) only at the eptifibatide concentration of 24 μg/mL and no change in a angle, whereas with the batroxobin-based TEG®, the difference in MA and α angle was observed at concentrations ≥0.8 μg/mL. Additionally, the time to achieve maximum MA was much shorter for batroxobin TEG® than for kaolin TEG®. We conclude that the batroxobin-modified TEG® is a sensitive method that detects platelet inhibition induced by eptifibatide.

AB - We examined a novel method to detect platelet inhibition with thrombelastography (TEG®). We hypothesized that this method would be suitable for monitoring the antiplatelet effects of eptifibatide (Integrilin®). Whole blood from healthy volunteers was anticoagulated with 3.2% citrate or unfractionated heparin (7 IU/ mL). For the platelet aggregation test, both citrate and heparinized samples were spiked with increasing concentrations of eptifibatide (0, 0.2, 0.4, 0.8, 1.6, and 4 μg/mL). Conventional kaolin TEG® was performed with citrated samples, and batroxobin-modified TEG® was performed with heparinized samples, which were spiked with eptifibatide at concentrations of 0, 0.4, 0.8, 1.6, 4, 8, and 24 μg/mL. Adenosine 5′-diphosphate-induced platelet aggregation was reduced to 6.4% ± 2.9% (citrate) and 10.3% ± 4.8% (heparin) with eptifibatide at the concentration of 4 μg/mL. The kaolin TEG® showed a decrease in maximum amplitude (MA) only at the eptifibatide concentration of 24 μg/mL and no change in a angle, whereas with the batroxobin-based TEG®, the difference in MA and α angle was observed at concentrations ≥0.8 μg/mL. Additionally, the time to achieve maximum MA was much shorter for batroxobin TEG® than for kaolin TEG®. We conclude that the batroxobin-modified TEG® is a sensitive method that detects platelet inhibition induced by eptifibatide.

UR - http://www.scopus.com/inward/record.url?scp=9244240822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244240822&partnerID=8YFLogxK

U2 - 10.1213/01.ANE.0000136476.82598.88

DO - 10.1213/01.ANE.0000136476.82598.88

M3 - Article

C2 - 15562073

AN - SCOPUS:9244240822

VL - 99

SP - 1794

EP - 1799

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 6

ER -